Study of mir 145 promoter methylation status in patients with superficial urothelial bladder cancer treated with BCG (Bacille Calmette-Guerin)

Articles in Press

Document Type : Original Article

Authors

1 Professor of Medical Biochemistry &Molecular Biology Faculty of Medicine - Benha University

2 Assistant Professor of Medical Biochemistry & Molecular Biology Faculty of Medicine - Benha University

3 Assistant Professor of Urology Faculty of Medicine - Benha University

4 Faculty M.B.B.Ch of Medicine- Benha University

5 Assistant Professor of Medical Biochemistry& Molecular Biology Faculty of Medicine - Benha University

Abstract

Background: Bladder cancer (BC) is a highly prevalent disease of the urinary system in the global population and is ranked as the fifth most common cancer in Western countries. Objective: To assess the promoter methylation status of microRNA-145 in patients with superficial bladder carcinoma who have undergone treatment with BCG, as well as to evaluate the potential correlation between the microRNA-145 methylation status and various clinicopathological parameters in these patients. Methods: This prospective interventional comparative study was conducted at departments of Urology and Medical Biochemistry & Molecular Biology, Faculty of Medicine, Benha University during the period from Jan 2022 to Dec 2022. 50 subjects. Patients were classified into two groups: Control group: included 22 subjects underwent cystolithotripsy or cystolithotomy and after completion of the procedure, cystoscopic bladder exploration was performed to assure that the bladder was free of any form of ulcerations and patients Group: included 28 patients had superficial bladder lesions amenable for in-situ management.Results: The median percentage of promoter methylation of patient’s specimens was significantly (P

Keywords

Benha Medical Journal

Articles in Press, Accepted Manuscript
Available Online from 26 July 2024

Files

Share

How to cite

Statistics